JMP Securities analyst Devin Ryan maintained a Hold rating on Moelis (MC – Research Report) yesterday. The company’s shares closed last Wednesday at $68.56, close to its 52-week high of $72.64.
According to TipRanks.com, Ryan is a top 100 analyst with an average return of 31.3% and a 84.0% success rate. Ryan covers the Financial sector, focusing on stocks such as Perella Weinberg Partners, Pennantpark Floating Rate, and Apollo Global Management.
Moelis has an analyst consensus of Hold, with a price target consensus of $73.00, a 3.5% upside from current levels. In a report issued on October 18, Morgan Stanley also maintained a Hold rating on the stock with a $73.00 price target.
See the top stocks recommended by analysts >>
Based on Moelis’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $361 million and net profit of $79.34 million. In comparison, last year the company earned revenue of $160 million and had a GAAP net loss of $5.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moelis & Co. operates as a holding company. It engages in the provision of financial advisory, capital raising, and asset management services to a client base including corporations, governments, and financial sponsors. It focuses on clients from large public multinational corporations to middle market private companies to individual entrepreneurs. The company was founded by Kenneth David Moelis, Navid Mahmoodzadegan, Jeffrey Raich, and Elizabeth Ann Crain in July 2007 and is headquartered in New York, NY.
Read More on MC:
- Whitestone REIT (WSR) Gets a Hold Rating from JMP Securities
- Analysts Offer Insights on Technology Companies: Pegasystems (PEGA) and Dynatrace (DT)
- Analysts Offer Insights on Financial Companies: AGNC Investment (AGNC), Amerisafe (AMSF) and Mid-America Apartment (MAA)
- JMP Securities Thinks Taysha Gene Therapies’ Stock is Going to Recover
- ServiceNow (NOW) Gets a Buy Rating from William Blair
